What Is Chronic Myeloid Leukemia?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Chronic myeloid leukemia (CML) is a cancer of the blood in which too many granulocytes, a type of white blood cell, are produced in bone marrow. Normally, bone marrow cells mature into several different types of blood cells. CML affects the young blood cells (called blasts).

An estimated 4,830 new cases of CML will be diagnosed in 2008, according to the American Cancer Society. CML is most common in older adults. The average age of diagnosis is about 55 to 60 years, with children only making up 2 percent of cases, according to the American Cancer Society.

The main function of granulocytes is to destroy bacteria. The blasts do not completely mature and become too numerous. They live longer than normal granulocytes and accumulate in the bone marrow and blood.

Initially in CML, there is a gradual increase in mature, abnormal myeloid cells in the bone marrow. These cells eventually spill into the blood and other organs, causing symptoms, such as fatigue from anemia or an enlarged spleen.

The increase in leukemia cell numbers occurs slowly at first and is referred to as the chronic phase. Eventually, the leukemia cells begin to increase more rapidly, resulting in the accelerated and blastic phases. CML can occur over a period of months or years.

Like most cancers, early detection and treatment can help control the disease or eliminate it from your body.

This content was last modified on August 11, 2007 .
Latest Chronic Myeloid Leukemia News
Novartis leukemia drugs show promise

December 9, 2008 — ZURICH (Reuters) - Novartis AG's cancer drug Tasigna was effective and helped achieve rapid responses as an initial therapy in newly diagnosed patients with a life threatening form of leukemia, the company said.

New study backs solvent, leukemia link

November 18, 2008 — NEW YORK (Reuters Health) - Research from Italy provides new evidence that exposure to the industrial solvent benzene increases a person's risk of developing multiple myeloma.

Gene trawl shows curing cancer harder than thought

September 4, 2008 — WASHINGTON (Reuters) - Cancer experts who probed every gene in tumors from two of the hardest-to-treat cancers found that cancer is much more complicated than anyone thought -- and say they found why a cure is so unlikely after a tumor has spread.

Select news items provided by Reuters Health